This article is more than 5 years old. Information may no longer be current.
JELIS: Fish oil reduced coronary events
DALLAS — A fish oil supplement added to statin therapy reduced cardiovascular events in the JELIS trial. Mitsuhiro Yokoyama, MD, at Kobe University School of Medicine, reported that these results seemed independent of cholesterol lowering.
JELIS (Japan EPA Lipid Intervention Study), presented at the AHA Scientific Sessions, enrolled 18,645 patients with mean total cholesterol of 275 mg/dL and mean LDL of 182 mg/dL.
All patients received a statin — either 10 mg/day pravastatin or 5 mg/day simvastatin — in the randomized, multicenter trial; the active treatment group also received 1,800 mg/day of the supplement. Major coronary events were significantly reduced by 19% in the combination therapy group; adverse events were also higher in that group.
